ABSTRACT Excessive consumption of energy and fat increases the risk for obesity. Snacks containing sucrose polyesters (SPE) as a dietary fat replacer are on the market in the United States. SPE products have been shown to lower concentrations of serum carotenoids in short-term studies. Experimental studies on the longer-term effects on health of decreased carotenoid concentrations are lacking. A 1-y randomized, double-blind, placebocontrolled parallel trial was performed. Subjects (n ϭ 380) with a habitual low or high fruit and vegetable intake were assigned to the treatments (0, 7, 10 or 17 g/d SPE). SPE was given in the form of spreads, chips or both. The groups were compared for serum carotenoids, vitamins and markers of oxidative damage, eye health, cardiovascular health and immune status. After 1 y, serum lipid-adjusted carotenoids showed the largest decrease in the SPE chips and spread group (17 g/d) compared with the control group [␣-carotene 33%; ␤-carotene 31%, lycopene 24%, ␤-cryptoxanthin 18%, lutein 18% (all P Ͻ 0.001) and zeaxanthin 13% (P Ͻ 0.05)]. Consumption of SPE spread (10 g/d SPE) decreased carotenoid concentrations by 11-29% (all P Ͻ 0.05). SPE chips (7 g/d SPE) decreased zeaxanthin (11%), ␤-carotene (12%) and ␣-carotene (21%; all P Ͻ 0.05). Serum lipid adjusted ␣-tocopherol decreased significantly by 6 -8% (all P Ͻ 0.001) in all SPE groups. No negative effects were observed on markers of oxidation, eye health, cardiovascular health or immune status. This study shows that decreases in serum carotenoid concentrations do not affect possible markers of disease risk. J. Nutr. 133: 720 -726, 2003. 
A high intake of fat is associated with an increased risk of obesity. Replacement of fatty foods by foods containing low or zero energy fat may be effective in reducing the energy intake of the population. A few years ago, low fat savory snacks containing sucrose polyester (SPE) 2 as a fat replacer (Olean, olestra) were introduced in the United States. It has been shown that products containing SPE fat substitutes can lower concentrations of serum carotenoids (1) and fat-soluble vitamins (2, 3) . Because SPE hampers the absorption of fat-soluble nutrients, the U.S. Food and Drug Administration (FDA) requires the addition of vitamins A, D, E and K to foods made with olestra (4) . The addition of carotenoids was not mandatory because the health effects of carotenoids are less well understood (5) .
Carotenoids are fat-soluble compounds and occur naturally in fruit and vegetables. In addition to the best-established function of ␤-carotene and to a lesser extent ␣-carotene and ␤-cryptoxanthin as precursors of vitamin A (6,7), carotenoids have other biological functions and actions. Carotenoids demonstrate in vitro antioxidant activity (8 -10) and protect the skin through their singlet oxygen-quenching capacity (11) . Furthermore, cell-to-cell communication (12) and immunomodulatory effects (13, 14) have been reported. Accumulation of lutein and zeaxanthin in the macula pigment of the retina could protect the eye by blue light filtering and singlet oxygen quenching (15) . It has been suggested that carotenoids through these biological functions and actions may protect against degenerative diseases, for example, cardiovascular disease (16, 17) , cancer (16, 18) and age-related macular degeneration (15, 16) .
In addition to SPE products, more foods that adversely affect carotenoids may be introduced. For instance, cholesterol-lowering phytosterol and stanol products also reduce carotenoid concentrations, albeit to a lesser extent (19, 20) . The longer-term effects as well as the functional consequences of decreased carotenoid concentrations have not been studied previously in detail in human intervention studies. Therefore, we conducted a 1-y human intervention trial to investigate the possible effects of SPE consumption on serum carotenoid and fat-soluble vitamin concentrations and markers of oxidative damage and also functional markers of eye health, cardiovascular health and immune status.
SUBJECTS AND METHODS
Subjects and study design. Between June 29, 1998 and September 8, 1999, we conducted a double-blind, randomized, placebocontrolled, parallel design trial with four treatment groups to study the effects of long-term SPE consumption. The study was performed according to International Conference on Harmonization guidelines for good clinical practice. The protocol was approved by an external Medical Ethical Committee.
Subjects were recruited through advertising. Respondents who expressed potential interest received information and a questionnaire on fruit and vegetable consumption and lifestyle (21) . The main exclusion criteria were age not between 18 and 75 y, pregnant women or women who wanted to become pregnant during the study and/or lactating women, serum cholesterol Ͼ7.5 and/or triacylglycerol Ͼ2.3 mmol/L if not under stabilized hypercholesterolemia/hyperlipidemia treatment, anticoagulant therapy, and vegetarians and vegans.
A total of 2734 of 6900 questionnaires were returned. Respondents ranked in the highest quintile of fruit and vegetable consumption (n ϭ 547) and those in the lowest tertile (n ϭ 775) were invited for an oral briefing. This preselection was made to select volunteers with a relatively high or low serum carotenoid status. Volunteers (n ϭ 589) gave their informed consent and filled in a questionnaire on personal data, life style, medical history and dietary habits. Failure to meet the criteria for serum cholesterol and/or triacylglycerol excluded 54 volunteers; 155 volunteers withdrew before the start of the study, leaving a total of 380 volunteers in this study at d 1.
Subjects were randomly assigned to one of the four treatment groups orthogonally balanced for high/low fruit and vegetable consumption. Age, gender and smoking status (yes/no) were used as randomization parameters thus assuring homogeneous distributions over the treatment groups. In June 1998, 85 subjects entered the study; 115 subjects entered in August 1998 and 180 subjects entered the trial in September 1998. The subjects consumed SPE in different concentrations and food products, e.g., spread and chips (deep-fried potato slices). The four treatment groups consumed control spread and control chips (control group), or SPE spread and control chips (SPE spread group), or control spread and SPE chips (SPE chips group), or SPE spread and SPE chips (SPE spread ϩ SPE chips group). The concentrations of SPE and triacylglycerol (TAG) of the products are given in Table 1 . All data in Table 1 are weighed means over all portions consumed from the various product batches.
Chips containing SPE (olestra) were purchased in the United States. Control chips were purchased in the Netherlands and the United States. All chips were repackaged in neutral bags in weekly portions of 200 g. Spreads were produced using pilot plant votator equipment at Unilever R&D Vlaardingen, according to regular spread processing procedures. The test spread contained 50% SPE and 35% TAG. The control spread was a low fat spread containing 35% TAG. More detailed data are given in Table 1 . The mean portion size of one tub of each spread was 140 g, intended for consumption within 1 wk. SPE raw materials for use in the test spreads were also produced at Unilever according to methods comparable to those described for the production of olestra.
The spreads were consumed as part of a normal dietary intake with an intended daily dosage of 20 g/d (thus either 0 or 10 g SPE/d, plus 7 g TAG). Subjects were instructed not to use the spread for cooking or baking. The chips were to be consumed as a snack in an amount of 200 g/wk, without a daily usage requirement. This led to an average consumption of 7 g/d SPE in test chips or 9 g/d TAG in control chips. The SPE dose of the chips is comparable to that used by the FDA to estimate chronic (lifetime) olestra intake by the 90th percentile snack eater. We estimated the SPE intake from spreads at an intake level somewhat above the fat intake from a mean margarine intake in the United States, which is 11 g/d of margarine, or ϳ8 g/d of fat.
The SPE spreads were enriched with vitamin A, D, E and K at vitamin/g SPE required by the FDA for the use of olestra in chips. We assumed that the same vitamin levels were present in the SPE chips taken from the market, but analyses showed that the test chips in fact contained 170% on average of the mandatory vitamin levels. The control spreads were enriched with vitamins A and D at levels (on product) as required by the Dutch law. The control chips were not fortified. The detailed vitamin composition of the study substances is given in Table 1 .
Distribution of the study products occurred in monthly intervals with four 140-g tubs (weekly portion) of spread and four bags containing of 200 g of chips. Returned spread tubs and chips bags were counted and registered and when a tub or a bag was not empty, the amount left was weighed and registered.
Morning blood samples were taken from fasting subjects at baseline and after 13, 26 and 52 wk. Serum and plasma were stored at Ϫ20 or Ϫ80°C. During the 52-wk study, 39 subjects dropped for several reasons, generally not treatment related: control group 10; SPE chips group 8; SPE spread group 9; SPE spread ϩ SPE chips group 12. However, the drop-outs in the SPE spread ϩ SPE chips group reported slightly more gastrointestinal (GI) complaints.
Analyses of products. The total fat content and the content of SPE and TAG in the products were analyzed using gel permeation chromatography after extraction of the total fat phase, according to internal methods. The vitamin contents of the study substances were analyzed at the RIKILT-DLO Institute in Wageningen, The Netherlands. After extraction with heptane, the carotene and total tocopherols content were analyzed by HPLC. Several other analyses were conducted to verify the quality and consistency of the various product batches.
The SPE raw materials used for the production of test spreads were analyzed for all parameters used in the specification of olestra by the FDA. The stiffness and the degree of esterification (of fatty acids on sucrose) were slightly different from the specification; all other parameters were within the specifications. The composition of the olestra material in the test chips was not analyzed. 3 290 ng cholecalciferol/g SPE in SPE spread and 529 cholecalciferol ng/g SPE in SPE chips (FDA requirement: 300 ng cholecalciferol/g SPE). 4 2.34 mg d-␣-tocopheryl acetate/g SPE in SPE spread and 3.51 mg d-␣-tocopheryl acetate/g SPE in SPE chips (FDA requirement: 2.07 mg d-␣-tocopheryl acetate/g SPE). 5 6.7 g 3-phytyl menadione/g SPE in SPE spread and 12.2 g 3-phytyl menadione/g SPE in SPE chips (FDA requirement: 8.0 g 3-phytyl menadione/g SPE).
Body weight. Body weight was assessed by weighing subjects wearing indoor clothing, without shoes, wallet and keys at monthly intervals.
Biochemical analyses. Serum carotenoids (CV, 3.7-14.9%), retinol (2.5%) and ␣-tocopherol (2.8%) and vitamin C (10%) were quantified by reversed-phase HPLC (21) . Tocopherol, retinol and carotenoids were quantified by fluorometric and diode array detection. Vitamin D (25-hydroxycholecalciferol) was quantified by competitive protein-binding assay as previously described with slight modifications (CV, 11%) (22) . Vitamin K (phylloquinone) in serum was assessed by HPLC with 2Ј,3Ј-dihydrophylloquinone as internal standard (CV, 8%).
LDL-oxidation was measured according to Esterbauer et al. (23) by continuous monitoring of in vitro oxidation of human LDL in ϳ50% of the study group. The lag time (lag-phase) was used as an objective procedure for determining the susceptibility of LDL. DNA damage, measured as the comet assay after induction with hydrogen peroxide (H 2 O 2 ), was conducted as described by Collins et al. (24) . The DNA strand breaks were analyzed in H 2 O 2 -treated isolated human peripheral blood mononuclear cells (to monitor resistance of the cells to oxidative stress). Plasma 8-epi-prostaglandin F 2␣ was measured according to a method described by Nourooz-Zadeh et al. (25) with some modifications. This method involves solid-phase extraction and conversion to pentafluorobenzyl ester and trimethylsilyl ether derivates. 8-Epi-prostaglandin F 2␣ was quantified using negativeiron chemical ionization high resolution mass spectrometry. Plasma protein carbonyl content was quantified by the reaction with 2,4-dinitrophenylhydrazine using an ELISA as previously described (26) .
Total osteocalcin and osteocalcin carboxylation degree was measured using an immunoradiometric assay with and without in vitro binding to hydroxyapatite (27, 28) . Tissue plasminogen activator (tPA) activity was measured by a biological immunoassay according to Meijer et al. (29) . tPA antigen level was measured with an ELISA using the Imulyse t-PA kit of Biopool (30) . The amount of prothrombin fragment 1.2 (F1 ϩ F2) was detected by Sandwich ELISA, using Enzygnost F1 ϩ 2 micro method from Dade-Behring, Marburg, Germany (31) . D-dimers were measured, using the Enzygnost micro method from Dade-Behring (32). Fibrinogen was detected according to Clauss (33) using the STA fibrinogen kit on a STA analyzer. C-reactive protein (CRP) was analyzed in plasma by an enzyme-immunoassay using polyclonal antibodies (Dako, Copenhagen, Denmark) with a low detection limit to detect basal levels in serum (34) . Soluble intercellular adhesion molecule-1 (sICAM-1) in plasma was determined with an immunoenzymometric method (35) .
Subjects known not to be vaccinated against hepatitis B received standard doses (20 g hepatitis B surface antigen/dose) of hepatitis B vaccine (Engerix-B, SmithKline Beecham Farma BV, Rijswijk, The Netherlands) intramuscularly (m. Deltoideus) at wk 39, 43 and 48 of the study. Anti-hepatitis B antibodies were determined using ELISA in serum samples at wk 39, 43, 48 and 52 (Hepanostika Anti-HBs microELISA test kit, Organon Teknika N.V. Turnhout, Belgium).
Total cholesterol, HDL cholesterol and triacylglycerol were analyzed by enzymatic techniques (Boehringer, Mannheim, Germany).
LDL cholesterol was calculated according to the Friedewald formula (36) .
Other measurements. Macular pigment density was measured as a marker of lutein and zeaxanthin in the eye by spectral reflectance analysis with the Utrecht Retinal Densitometer (37) . A previous study using the same method showed a within subject variation coefficient of 17% (38). The minimal erythema dose (MED) quantifies the sensitivity of the skin to solar UV irradiation by exposing the skin to increasing UV dosages as described previously (39) with a CV Ͻ12.5%.
Flow-mediated vasodilation (FMD) of the brachial artery was measured as a marker of endothelial function in ϳ50% of the study group (40) . The diameter of the artery at rest and at maximum vasodilatation was used to calculate the percentage FMD.
Adverse events were classified according to the WHO (41). GI symptoms were reported using a self-reporting questionnaire.
Statistical analyses. Data were expressed as means Ϯ SD for each treatment. To correct for changes in serum lipid concentrations, we present percentage changes in lipid standardized carotenoid and ␣-tocopherol concentrations. Serum lipid-adjusted carotenoid concentrations were calculated as follows: [carotenoid concentration/(total cholesterol ϩ triacylglycerol)]. Overall, differences in changes (wk 52 -wk 0) between groups were tested by ANOVA with treatment as factor using the F-test at an ␣ ϭ 5% significance level (PROC GLM, SAS/STAT software, version 6.12, SAS Institute, Cary, NC). If a significant overall treatment effect was detected, the least significant difference (LSD) using a two-sided significance level of ␣ ϭ 5%, based on the ANOVA mean-squared error, was used to determine which groups were different. In addition, differences in study variables were evaluated using two-sided ANOVA with treatment and prestudy low and high fruit and vegetables consumption as factors. When a significant difference was found, the least significant difference (LSD) was used to determine which groups were different. Furthermore, differences among treatment groups in study variables for only low fruit and vegetable consumers, smokers or elderly with treatment as factor were evaluated using ANOVA.
If data were not normally distributed, data were natural log transformed before ANOVA. Antibodies against hepatitis B are presented for wk 52. Effects were evaluated by assessment of the amount of antibodies formed and by counting the number of subjects who were seroconverted (hepatitis B antibodies Ͼ10 IU/L). If volunteers were already seroconverted for hepatitis B at wk 39 they were excluded from statistical analysis.
RESULTS
Baseline characteristics. The baseline characteristics of the four treatment groups were similar ( Table 2) ; 341 subjects (164 men and 177 women) completed the study.
Adverse events and gastrointestinal effects. No differences in adverse events were observed among the treatment groups. Three serious adverse events occurred that were likely not related to the treatment (control group 1; SPE spread group 1; SPE spread ϩ SPE chips group 1). The GI questionnaire showed no clear effects of SPE consumption. (data not statistically tested).
Compliance and eating moment. Consumption of spread and chips was evaluated after 13, 26 and 52 wk and did not differ among the groups. The overall compliance was good, Ͼ98.8% in all groups. Spreads was consumed mainly on bread; ϳ10% of the consumers of the SPE chips group, control group, SPE chips ϩ spread group used the spread on their vegetables. However, more (27% at week 8 and 20% at week 52) consumers of the SPE spread group used spread on bread as well on vegetables. Chips were consumed mainly as a snack with a frequency of 3-5 times/wk. Only ϳ1-6% used chips as snack and with dinner, and only ϳ1% used the chips with dinner throughout the study in the four treatments groups.
Body weight. After 1 y of intervention, body weight (ϮSD) increased by 1.5 Ϯ 2.9 kg (2.0 Ϯ 3.8%) in the control group, 0.5 Ϯ 3.4 kg (0.7 Ϯ 4.5%) in the SPE chips group, 1.2 Ϯ 2.4 kg (1.6 Ϯ 3.2%) in the SPE spread group and 0.5 Ϯ 3.2 kg (0.7 Ϯ 4.2%) in the SPE spread ϩ SPE chips group. These changes in body weight did not differ among the groups after 1 y (P Ͼ 0.05).
Carotenoids, vitamins and lipids. The greatest reductions were observed for ␣-carotene (Ϫ0.02 Ϯ 0.05 mol/L), ␤-carotene (Ϫ0.15 Ϯ 0.17 mol/L) and lycopene (Ϫ0.10 Ϯ 0.15 mol/L) in the SPE spread ϩ SPE chips group. Compared with the control group, lipid standardized concentrations of carotenoids decreased by 33% (P Ͻ 0.0001) for ␣-carotene, followed by ␤-carotene (31%; P Ͻ 0.0001), lycopene (24%; P Ͻ 0.001), ␤-cryptoxanthin (18%; P Ͻ 0.0001), lutein (18%; P Ͻ 0.0001) and zeaxanthin (13%; P Ͻ 0.001) in the SPE chips ϩ SPE spread group.
In the SPE spread group, ␣-carotene, ␤-carotene and lycopene decreased by 0.02 Ϯ 0.05, 0.13 Ϯ 0.19 and 0.07 Ϯ 0.17 mol/L, respectively. Lipid standardized serum carotenoid concentrations decreased significantly by 11% for lutein and zeaxanthin (P Ͻ 0.05), 14% (P Ͻ 0.05) for ␤-cryptoxanthin, 19% (P Ͻ 0.05) for lycopene, 25% (P Ͻ 0.0001) for ␤-carotene and 29% (P Ͻ 0.0001) for ␣-carotene (P Ͻ 0.0001) in comparison with the control group.
Lipid-standardized serum zeaxanthin, ␣-carotene, ␤-carotene decreased significantly by 11% (P Ͻ 0.05), 21% (P Ͻ 0.05), 12% (P Ͻ 0.05) in the SPE chips group in comparison with the control group, respectively. No significant differences between the control group and SPE chips group were found for lutein, ␤-cryptoxanthin and lycopene.
Despite supplementation of test products with vitamin E, lipid-standardized serum ␣-tocopherol decreased by 8% (P Ͻ 0.0001) in the SPE spread ϩ SPE chips group, 6% (P Ͻ 0.001) in the SPE spread group and 7% (P Ͻ 0.0001) in the SPE chips group compared with the control group. The changes in vitamins A (retinol), C, D and K concentrations did not differ among the groups (data not shown).
At three time points after the study (15-35, 41-58 and 64 -91 d), serum carotenoids and ␣-tocopherol concentrations were not significantly different between the control group and SPE spread ϩ SPE chips group. Changes in LDL cholesterol coincided with those in total cholesterol, i.e., LDL cholesterol increased significantly more in the SPE chips group (8.4%) than in the control group (3.2%; P Ͻ 0.05) and the SPE spread ϩ SPE chips group (0.8%; P Ͻ 0.05). In addition, LDL cholesterol increased significantly more in the SPE spread group (6.4%; P Ͻ 0.05) compared with the SPE spread ϩ SPE chips group. The changes in HDL cholesterol did not differ among the four groups at wk 52 ( Table 4) .
Increases in triacylglycerol (TAG) were significantly higher in the group consuming SPE chips (31.4%) compared with the SPE spread group (9.6%; P Ͻ 0.05) and the SPE spread ϩ SPE chips group (13.8%; P Ͻ 0.05). Consumers of SPE spread ϩ SPE chips or only SPE spread did not differ in changes in triacylglycerol, total, and LDL cholesterol concentrations compared with the control group after 52 wk (Table 4) .
Oxidation markers. No differences were found among the four treatment groups for lag time (LDL-oxidation), protein Functional markers. The changes in macula pigment (MP) density did not differ among the groups. The median values (25th-75th percentiles) of the individual percentage changes of MP density were 6.5% (Ϫ8.1 Ϫ 28.8), 3.8% (Ϫ14.3 -34.7), 5.1% (Ϫ9.9 -34.5) and 1.7% (Ϫ16.9 -36.0) in the control, SPE chips, SPE spread and SPE spread ϩ SPE chips group, respectively. Because of technical problems with the densitometer, 83 measurements were not performed in wk 52. Within a 10-wk period after wk 52, however, MP density measurement was repeated in 45 subjects. Exclusion of these data did not affect previous results.
There were no significant differences in changes in mean calculated endothelial function among the treatment groups as measured by flow-mediated vasodilation (data not shown). SPE consumption had no effects on immune function. The number of seroconverted subjects did not differ among the groups, nor did the antibody titer against hepatitis B (data not shown).
DISCUSSION
This study shows that serum carotenoid decreases resulting from consumption of sucrose polyesters do not affect possible markers of disease risk after 1 y. Among the strengths of our study are the large study group, double-blind placebo-controlled 1-y study design, good reported compliance and the free-living conditions. Overall, a dose-response existed between SPE consumption and serum carotenoid concentrations, with the largest decrease of all carotenoids in the group consuming both SPE chips and spread and a decrease of only zeaxanthin, ␣-carotene and ␤-carotene after SPE chips consumption. However, this difference in serum carotenoid changes could also be caused by consumption of different food products and consumption patterns. On the basis of the results of consumption patterns of the study products in this study, we suggest that the co-consumption of these SPE products with carotenoid-containing foods, which has an influence on the carotenoid decreases, was minimal in the treatment groups, although we lack exact information. In this study, we wanted to mimic the habitual intake of chips and spread, which are normally not consumed together with carotenoid-containing foods. However, we cannot generalize our results to SPE products that are consumed with carotenoid-containing foods.
The reductions in serum carotenoids after SPE consumption reported here are comparable to the reductions reported for short-term trials (1-3,42) . The most lipophilic hydrocarbon carotenoid concentrations (␣-carotene, ␤-carotene and lycopene) showed larger changes than the more polar oxygenated carotenoids (lutein, zeaxanthin and ␤-cryptoxanthin), especially in the group with the highest SPE intake. Results of short-term trials indicate that daily consumption of SPE may reduce the serum concentrations of carotenoids very rapidly, but a new steady-state level is reached within 4 wk. In this trial, we observed a steady state within 13 wk, except for ␤-cryptoxanthin (Fig. 1) .
The first results of the sentinel site of the Olestra Post Marketing Surveillance Study showed that reductions between 
FIGURE 1
Mean carotenoid concentrations at wk 0, 13 and 52 in subjects with a habitual low or high fruit and vegetable intake assigned to the sucrose polyester (SPE) spread ϩ SPE chips group. Values are means Ϯ SEM, n ϭ 81.
baseline and follow-up of 1 y in the highest category of SPE consumption were 21% for ␤-carotene (compared with 7% for nonconsumers) and 7% for lycopene (compared with no change for nonconsumers). None of these effects in that analysis was significant and there were no dose-response relationships between olestra and serum carotenoids (43) . These smaller reductions in serum carotenoids are most likely due to a lower SPE consumption.
In the present study, concentrations of the lipid-soluble vitamins, retinol, 25-OH vitamin D and vitamin K, were not affected by the study substances containing SPE enriched with vitamins A, D and K. Plasma vitamin K is not the best indicator of vitamin K status. Therefore, we also measured total osteocalcin and osteocalcin carboxylation degree. The changes in these variables were also not affected by the treatments after 1 y (data not shown). This suggests that the mandatory enrichment with these vitamins was sufficient to offset any SPE effects on lipid-soluble vitamin absorption, although the actual enrichment of SPE chips was higher than required by the FDA. However, we report that lipid-adjusted serum concentrations of ␣-tocopherol were affected by SPE consumption irrespective of product format despite the enrichment with ␣-tocopheryl acetate. Our study population consisted of consumers with a low or high fruit and vegetable consumption. Therefore, it is difficult to make a recommendation for the enrichment of ␣-tocopherol acetate for the general population. However, the enrichment of SPE chips was already 70% higher than required. This enrichment was not sufficient for this study population. The major objective of this study was to examine the effects of carotenoid decreases on possible markers of oxidative damage and functional markers related to eye health, cardiovascular health and immune status. We did not observe any negative effects on these markers after 1 y. It should be noted that for almost all markers, the relationship between these markers and the final disease risk has to be established.
Results of published supplementation studies with carotenoids are not completely consistent concerning the effect on biomarkers of oxidative damage. We did not observe an effect on these markers after significant decreases of carotenoid concentrations. Our results are in line with the observation that olestra consumption is not associated with reduced MP optical density in a free-living population (44) . In that study, serum lutein and zeaxanthin concentrations were not affected, possibly because of a lower intake of SPE than in our study. Both studies were limited by the duration of 1 y; however, intervention studies whose goal was to increase serum carotenoids showed an increase of both MP density (38,45) and MED (46, 47) within several weeks. Johnson et al. (45) showed that consumption of spinach and corn with the daily diet resulted in an increase of 0.07 (ϳ18%) in MP density after 15 wk. In the study of Stahl et al. (46) erythema was 40% lower in subjects consuming tomato paste, and serum lycopene was onefold higher after 10 wk. A posteriori power analysis indicated that we could have detected a difference of 0.055 in MP density and 0.075 in MED between treatments. Our study showed that 18% decrease in serum lipid-adjusted lutein and 24% decrease in serum lipid-adjusted lycopene over 1 y did not have negative effects on MP density and MED.
The present study does not demonstrate any negative effects of lower concentrations of serum carotenoid and ␣-tocopherol on FMD. However, it should be noted that the within-subject variability of FMD is large, ϳ50% of the mean response (48) . With our number of subjects, we could detect a difference of 3.3%-points in FMD with a probability of 0.05 and a power of 0.80.
There are indications that the antioxidants ␤-carotene and vitamin E could have immunoenhancing effects (49 -51). Our results indicate no negative effects of carotenoid and ␣-tocopherol decreases on the primary adaptive immunity as measured by antibody production to a model infection mimicked by hepatitis B vaccination. In addition, we did not observe negative effects on clinical chemical variables, hematological variables, coagulation/fibrinolysis and inflammation markers, including t-PA antigen, t-PA activity, F1 ϩ F2, fibrinogen, D-dimers, CRP and sICAM-1 (data not shown).
Although this study was not specifically designed to evaluate the possible body weight-and cholesterol-lowering effect of SPE when consumed as dietary fat replacers, we did not observe a clear effect on serum lipids concentrations and body weight after daily SPE consumption for 1 y. In an observational study, Patterson et al. (52) reported that frequent consumers of olestra, those with 2 servings of chips per week for 1 y, experienced a decrease of 10% in total serum cholesterol and a reduction in dietary fat intake. In the study of Patterson et al. (52) , heavy users lost about a pound of weight, whereas weight remained stable among nonconsumers. These authors suggested that olestra consumption is probably an indicator of a healthier lifestyle in general.
In this study, we evaluated the effects in an average Dutch population, including subjects from subpopulations probably more at risk for the effects of carotenoid decreases such as elderly, smokers and habitual low fruit and vegetable consumers. Our observations show that in these subpopulations, functional markers were also not affected by the consumption of SPE (data not shown).
In observational studies, it has consistently been shown that higher serum carotenoid concentrations are related to a decreased risk of chronic diseases. However, intervention studies that aimed to increase serum carotenoids by supplementation with ␤-carotene could not confirm this protective effect against chronic diseases. Our study suggests that decreases in serum carotenoids do not affect possible markers of disease risk.
